BioHedge Weekly
13D/13G filings from 17 institutional investors, cross-referenced with trial events and regulatory filings. Part of the RxDataLab platform — clinical trials, SEC filings, and hedge fund positioning, linked by company.
Weekly Filing Volume
Filings This Week
| Company | Fund | Ownership | Type |
|---|---|---|---|
| TRINITY BIOTECH (TRIB) | Perceptive Advisors | 9.9% | 13D/A [SEC] |
| SAB BIOTHERAPEUTICS INC (SABS) | Perceptive Advisors | 7.3% | New 13G [SEC] |
| Cogent Biosciences, Inc. (COGT) | Fairmount Funds Management LLC | 9.9% | 13D/A [SEC] |
| Apogee Therapeutics, Inc. (APGE) | Fairmount Funds Management LLC | 10.0% | 13D/A [SEC] |
New Positions
Funds disclosing >5% ownership in a company for the first time.
| Company | Fund | Ownership | Type |
|---|---|---|---|
| SAB BIOTHERAPEUTICS INC (SABS) | Perceptive Advisors | 7.3% | SC 13G [SEC] |
About This Data
Schedule 13D/13G filings are SEC disclosures that report beneficial ownership. They are required when an investor acquires more than 5% of a company's shares. Schedule 13D filings indicate activist intent (potential influence over company direction), while 13G filings indicate passive investment.
New positions are filings where a fund discloses >5% ownership in a company for the first time.
We track 17 biotech-focused institutional investors with known sector expertise.
Data from RxDataLab and the SEC.